Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2010

View Archived Issues

GDNF gene therapy shows promise in Parkinson's disease model

RAD-1901 is efficacious in phase IIa trial in postmenopausal women

Novel RAF kinase inhibitors emerge from Takeda R&D

First-in-human data presented on MLN-9708 in nonhematologic cancer

Serotonin receptor modulators discovered at Nanotherapeutics

Concert Pharmaceuticals claims new deuterated agents

Kagawa Medical University claims new angiogenesis-promoting agents

GSK claims calcium-sensing CaS receptor ligands

Pardoprunox is effective in PD but dose adjustment is needed

Phase III data detailed for add-on safinamide in PD

Versartis commences phase Ia trial of VRS-859 in type 2 diabetes

Reduced melanoma cell growth observed in in vitro testing of GAP-107B8

AstraZeneca and Targacept begin phase III program for TC-5214 in MDD

Phase I trial of XMT-1107 initiated in patients with refractory advanced solid tumors

Infinity enrolling patients in phase I trial of IPI-493 for hematologic malignancies

First patients enrolled in phase I/II study of PVS-10200 for prevention of restenosis

Cellceutix's KM-391shown to increase serotonin levels in preclinical study

Sanofi-aventis begins phase I trial of anticancer agent SAR-650984

Amorfix and QED to co-develop high-affinity monoclonal antibodies for cancer

Anthera begins enrollment in pivotal phase III study of varespladib

EndoTAG-1 effective in triple receptor-negative breast cancer in phase II trial

Merck receives FDA approval for Dulera for asthma in patients 12 years and older

Santaris and miRagen develop microRNA-targeted cardiovascular medicines

FDA advisory committee meeting scheduled to review Contrave NDA

Sanofi-aventis and Metabolex enter into licensing agreement for novel antidiabetic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Viva in vivo! At EHA, in vivo CAR T data continues to impress
BioWorld
Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...